Government and Life Science Industry Join Forces on 100 Days Mission for Future Pandemics

Government and Life Science Industry Join Forces on 100 Days Mission for Future Pandemics
04 June 2021
:: Landmark collaboration between Government and life sciences industry leaders to join mission to protect against future pandemic threats and slash time to develop and deploy new diagnostics, therapeutics and vaccines to 100 days.
:: Intention to work towards the ambition of a 100 Days Mission follows crucial discussions at UK-hosted G7 Health Ministers’ and life sciences meetings in Oxford.
:: CEOs and representatives of life science companies discussed the emerging recommendations in the pandemic preparedness partnership roadmap, which Sir Patrick Vallance and Melinda French Gates will present to G7 Leaders at the Carbis Bay Summit next week.

Life science industry leaders are joining forces with governments to step up collective efforts to save lives from diseases and tackle global pandemics, with a new commitment for partnership working to achieve the ambition of better pandemic preparedness announced today at the conclusion of the G7 Health event on life sciences.

Following discussions at the G7 Health Ministers’ Meeting – hosted by the UK Government as part of its G7 Presidency – CEOs and representatives of companies among those leading the efforts to develop COVID-19 diagnostics, vaccines and treatments backed the ambition of the 100 Days Mission set out by the pandemic preparedness partnership.

The Government and industry leaders agreed to work towards a plan to develop and deploy high-quality diagnostics, therapeutics and vaccines in just 100 days after a new pandemic threat is identified. Success would take the great achievement of delivering COVID-19 vaccines in 326 days to the next level and protect people from potential future pandemics.

CEOs and representatives from some of the world’s largest life sciences companies participated in the UK’s G7 Health event on life sciences, which also included deliberations on how the public and private sectors can work together to combat antimicrobial resistance (AMR).

All the participants recognised the crucial importance of sustained political and industry leadership in between outbreaks and of the public and private sectors working together to tackle the most complex global health threats…

More information on the Pandemic Preparedness Partnership can be found here: https://www.g7uk.org/new-global-partnership-launched-to-fight-future-pandemics/

The following representatives from industry participated in the G7 event:
Dr Albert Bourla, CEO and Chairman of Pfizer
Dr Giovanni Caforio, CEO and Chairman of Bristol Myers Squibb
Marc Casper, CEO of Thermo Fisher Scientific
Thomas Cueni, DG, International Federation of Pharmaceutical Manufacturers and Association (IFPMA)
Robert Ford, CEO of Abbott
Lars Fruergaard Jorgensen, CEO of Novo Nordisk
Paul Hudson, CEO of Sanofi
Martin Meeson, CEO of Fujifilm Diosynth Biotechnologies
Vas Narasimhan M.D., CEO of Novartis
Daniel O’Day, CEO of Gilead
Stefan Oelrich, Member of the Board of Management of Bayer AG and President Pharmaceuticals
Tom Polen, CEO of BD
David Ricks, CEO and Chairman of Eli Lilly & Company
Dr Severin Schwan, CEO of Roche
Paul Stoffels M.D. Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson &
Johnson
Pascal Soriot, CEO of Astra Zeneca
Dame Emma Walmsley, CEO of GlaxoSmithKline
Christophe Weber, CEO of Takeda
Jean-Christophe Tellier, CEO of UCB & President of International Federation of Pharmaceutical
Manufacturers and Associations (IFPMA)